A Glimpse in the Future of Malignant Mesothelioma Treatment

Malignant mesothelioma (MMe) is a rare neoplasm with few therapeutic options available. The landscape of effective therapy for this disease remained unchanged in the last two decades. Recently, however, the introduction of Immune Checkpoint Inhibitors (ICIs) led to small, but nevertheless, promising...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2021-12, Vol.12, p.809337-809337
Main Authors: Pezzicoli, Gaetano, Rizzo, Mimma, Perrone, Martina, Minei, Silvia, Mutti, Luciano, Porta, Camillo
Format: Article
Language:English
Subjects:
antiangiogenics
immune checkpoint inhibitors
mesothelin
mesothelioma
microRNA
oncolytic viruses
Pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c465t-6c21d4227072d9c22d7c1dc3a01fd24ea832818d72b12996735e535aa50ddd83
cites cdi_FETCH-LOGICAL-c465t-6c21d4227072d9c22d7c1dc3a01fd24ea832818d72b12996735e535aa50ddd83
container_end_page 809337
container_issue
container_start_page 809337
container_title Frontiers in pharmacology
container_volume 12
creator Pezzicoli, Gaetano
Rizzo, Mimma
Perrone, Martina
Minei, Silvia
Mutti, Luciano
Porta, Camillo
description Malignant mesothelioma (MMe) is a rare neoplasm with few therapeutic options available. The landscape of effective therapy for this disease remained unchanged in the last two decades. Recently, however, the introduction of Immune Checkpoint Inhibitors (ICIs) led to small, but nevertheless, promising improvements. However, many efforts are still needed to radically improve the prognosis of MMe. In this review, we analyze all those therapeutic strategies for MMe that are still in a preclinical or early clinical phase of development. In particular, we focus on novel antiangiogenic drugs and their possible combination with immunotherapy. Furthermore, we describe also more complex strategies such as microRNA-loaded vectors, oncolytic viruses, and engineered lymphocytes.
doi_str_mv 10.3389/fphar.2021.809337
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_9a1e80df1cb140dcbaeb4b4347eb7e98</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_9a1e80df1cb140dcbaeb4b4347eb7e98</doaj_id><sourcerecordid>2616279919</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-6c21d4227072d9c22d7c1dc3a01fd24ea832818d72b12996735e535aa50ddd83</originalsourceid><addsrcrecordid>eNpVkUtLJDEQgMOirKL-AC9LH73MmGcnYWFBZH2A4mXuoTqpnol0d2aTbsF_b4_jitYlRarqq4SPkHNGl0IYe9luN5CXnHK2NNQKoX-QY1bXYmEN4wdf8iNyVsoznUNYK2r5kxwJabVSVB2T31fVbRf7bcEqDtW4wepmGqeMVWqrR-jieoBhrB6xpLnWxdRDtcoIY4_DeEoOW-gKnn2cJ2R183d1fbd4eLq9v756WHhZq3FRe86C5FxTzYP1nAftWfACKGsDlwhGcMNM0Lxh3NpaC4VKKABFQwhGnJD7PTYkeHbbHHvIry5BdO8XKa8d5DH6Dp0FhoaGlvmGSRp8A9jIRgqpsdFod6w_e9Z2anoMfv5Fhu4b9HtliBu3Ti_OaCatUjPg4gOQ078Jy-j6WDx2HQyYpuJ4zWqurWV2bmX7Vp9TKRnbzzWMup1C967Q7RS6vcJ55tfX931O_Bcm3gC--Jgr</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2616279919</pqid></control><display><type>article</type><title>A Glimpse in the Future of Malignant Mesothelioma Treatment</title><source>PubMed Central Free</source><creator>Pezzicoli, Gaetano ; Rizzo, Mimma ; Perrone, Martina ; Minei, Silvia ; Mutti, Luciano ; Porta, Camillo</creator><creatorcontrib>Pezzicoli, Gaetano ; Rizzo, Mimma ; Perrone, Martina ; Minei, Silvia ; Mutti, Luciano ; Porta, Camillo</creatorcontrib><description>Malignant mesothelioma (MMe) is a rare neoplasm with few therapeutic options available. The landscape of effective therapy for this disease remained unchanged in the last two decades. Recently, however, the introduction of Immune Checkpoint Inhibitors (ICIs) led to small, but nevertheless, promising improvements. However, many efforts are still needed to radically improve the prognosis of MMe. In this review, we analyze all those therapeutic strategies for MMe that are still in a preclinical or early clinical phase of development. In particular, we focus on novel antiangiogenic drugs and their possible combination with immunotherapy. Furthermore, we describe also more complex strategies such as microRNA-loaded vectors, oncolytic viruses, and engineered lymphocytes.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2021.809337</identifier><identifier>PMID: 34975505</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>antiangiogenics ; immune checkpoint inhibitors ; mesothelin ; mesothelioma ; microRNA ; oncolytic viruses ; Pharmacology</subject><ispartof>Frontiers in pharmacology, 2021-12, Vol.12, p.809337-809337</ispartof><rights>Copyright © 2021 Pezzicoli, Rizzo, Perrone, Minei, Mutti and Porta.</rights><rights>Copyright © 2021 Pezzicoli, Rizzo, Perrone, Minei, Mutti and Porta. 2021 Pezzicoli, Rizzo, Perrone, Minei, Mutti and Porta</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-6c21d4227072d9c22d7c1dc3a01fd24ea832818d72b12996735e535aa50ddd83</citedby><cites>FETCH-LOGICAL-c465t-6c21d4227072d9c22d7c1dc3a01fd24ea832818d72b12996735e535aa50ddd83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714955/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714955/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34975505$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pezzicoli, Gaetano</creatorcontrib><creatorcontrib>Rizzo, Mimma</creatorcontrib><creatorcontrib>Perrone, Martina</creatorcontrib><creatorcontrib>Minei, Silvia</creatorcontrib><creatorcontrib>Mutti, Luciano</creatorcontrib><creatorcontrib>Porta, Camillo</creatorcontrib><title>A Glimpse in the Future of Malignant Mesothelioma Treatment</title><title>Frontiers in pharmacology</title><addtitle>Front Pharmacol</addtitle><description>Malignant mesothelioma (MMe) is a rare neoplasm with few therapeutic options available. The landscape of effective therapy for this disease remained unchanged in the last two decades. Recently, however, the introduction of Immune Checkpoint Inhibitors (ICIs) led to small, but nevertheless, promising improvements. However, many efforts are still needed to radically improve the prognosis of MMe. In this review, we analyze all those therapeutic strategies for MMe that are still in a preclinical or early clinical phase of development. In particular, we focus on novel antiangiogenic drugs and their possible combination with immunotherapy. Furthermore, we describe also more complex strategies such as microRNA-loaded vectors, oncolytic viruses, and engineered lymphocytes.</description><subject>antiangiogenics</subject><subject>immune checkpoint inhibitors</subject><subject>mesothelin</subject><subject>mesothelioma</subject><subject>microRNA</subject><subject>oncolytic viruses</subject><subject>Pharmacology</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkUtLJDEQgMOirKL-AC9LH73MmGcnYWFBZH2A4mXuoTqpnol0d2aTbsF_b4_jitYlRarqq4SPkHNGl0IYe9luN5CXnHK2NNQKoX-QY1bXYmEN4wdf8iNyVsoznUNYK2r5kxwJabVSVB2T31fVbRf7bcEqDtW4wepmGqeMVWqrR-jieoBhrB6xpLnWxdRDtcoIY4_DeEoOW-gKnn2cJ2R183d1fbd4eLq9v756WHhZq3FRe86C5FxTzYP1nAftWfACKGsDlwhGcMNM0Lxh3NpaC4VKKABFQwhGnJD7PTYkeHbbHHvIry5BdO8XKa8d5DH6Dp0FhoaGlvmGSRp8A9jIRgqpsdFod6w_e9Z2anoMfv5Fhu4b9HtliBu3Ti_OaCatUjPg4gOQ078Jy-j6WDx2HQyYpuJ4zWqurWV2bmX7Vp9TKRnbzzWMup1C967Q7RS6vcJ55tfX931O_Bcm3gC--Jgr</recordid><startdate>20211215</startdate><enddate>20211215</enddate><creator>Pezzicoli, Gaetano</creator><creator>Rizzo, Mimma</creator><creator>Perrone, Martina</creator><creator>Minei, Silvia</creator><creator>Mutti, Luciano</creator><creator>Porta, Camillo</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20211215</creationdate><title>A Glimpse in the Future of Malignant Mesothelioma Treatment</title><author>Pezzicoli, Gaetano ; Rizzo, Mimma ; Perrone, Martina ; Minei, Silvia ; Mutti, Luciano ; Porta, Camillo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-6c21d4227072d9c22d7c1dc3a01fd24ea832818d72b12996735e535aa50ddd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>antiangiogenics</topic><topic>immune checkpoint inhibitors</topic><topic>mesothelin</topic><topic>mesothelioma</topic><topic>microRNA</topic><topic>oncolytic viruses</topic><topic>Pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pezzicoli, Gaetano</creatorcontrib><creatorcontrib>Rizzo, Mimma</creatorcontrib><creatorcontrib>Perrone, Martina</creatorcontrib><creatorcontrib>Minei, Silvia</creatorcontrib><creatorcontrib>Mutti, Luciano</creatorcontrib><creatorcontrib>Porta, Camillo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pezzicoli, Gaetano</au><au>Rizzo, Mimma</au><au>Perrone, Martina</au><au>Minei, Silvia</au><au>Mutti, Luciano</au><au>Porta, Camillo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Glimpse in the Future of Malignant Mesothelioma Treatment</atitle><jtitle>Frontiers in pharmacology</jtitle><addtitle>Front Pharmacol</addtitle><date>2021-12-15</date><risdate>2021</risdate><volume>12</volume><spage>809337</spage><epage>809337</epage><pages>809337-809337</pages><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>Malignant mesothelioma (MMe) is a rare neoplasm with few therapeutic options available. The landscape of effective therapy for this disease remained unchanged in the last two decades. Recently, however, the introduction of Immune Checkpoint Inhibitors (ICIs) led to small, but nevertheless, promising improvements. However, many efforts are still needed to radically improve the prognosis of MMe. In this review, we analyze all those therapeutic strategies for MMe that are still in a preclinical or early clinical phase of development. In particular, we focus on novel antiangiogenic drugs and their possible combination with immunotherapy. Furthermore, we describe also more complex strategies such as microRNA-loaded vectors, oncolytic viruses, and engineered lymphocytes.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>34975505</pmid><doi>10.3389/fphar.2021.809337</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1663-9812
ispartof Frontiers in pharmacology, 2021-12, Vol.12, p.809337-809337
issn 1663-9812
1663-9812
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_9a1e80df1cb140dcbaeb4b4347eb7e98
source PubMed Central Free
subjects antiangiogenics
immune checkpoint inhibitors
mesothelin
mesothelioma
microRNA
oncolytic viruses
Pharmacology
title A Glimpse in the Future of Malignant Mesothelioma Treatment
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T22%3A15%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Glimpse%20in%20the%20Future%20of%20Malignant%20Mesothelioma%20Treatment&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Pezzicoli,%20Gaetano&rft.date=2021-12-15&rft.volume=12&rft.spage=809337&rft.epage=809337&rft.pages=809337-809337&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2021.809337&rft_dat=%3Cproquest_doaj_%3E2616279919%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c465t-6c21d4227072d9c22d7c1dc3a01fd24ea832818d72b12996735e535aa50ddd83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2616279919&rft_id=info:pmid/34975505&rfr_iscdi=true